What is Revance Therapeutics'price targets for the next year?
11 equities research analysts have issued 1 year price objectives for Revance Therapeutics' stock. Their predictions range from $17.83 to $50.00. On average, they expect Revance Therapeutics' stock price to reach $34.7288 in the next year.
Should you buy Revance Therapeutics (RVN) stock?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Revance Therapeutics stock.
What's new at Revance?
"Our latest scientific findings and introduction of new data underscores Revance’s commitment to the advancement of research of neurotoxins in both aesthetic and therapeutic indications, while reinforcing DaxibotulinumtoxinA for Injection’s differentiated performance profile," said Conor Gallagher, Vice President of Medical Affairs and Scientifi...
Can Revance’s novel peptide enhance membrane binding of BoNT/A?
– New data demonstrating the enhancement of membrane binding of the core neurotoxin of BoNT/A by RTP004, Revance’s novel, excipient peptide – – A podium presentation on ASPEN-1: A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia –
Is revance a good stock to buy?
Revance Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Will revance Therapeutics stock go up?
The 8 analysts offering 12-month price forecasts for Revance Therapeutics Inc have a median target of 27.50, with a high estimate of 55.00 and a low estimate of 22.00. The median estimate represents a +85.19% increase from the last price of 14.85.
Is RVNC stock a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There ar...
Will Revance Therapeutics' stock price go up in 2022?
5 equities research analysts have issued 12 month target prices for Revance Therapeutics' shares. Their forecasts range from $17.00 to $36.00. On a...
How has Revance Therapeutics' stock price performed in 2022?
Revance Therapeutics' stock was trading at $16.32 at the beginning of 2022. Since then, RVNC shares have decreased by 22.9% and is now trading at $...
When is Revance Therapeutics' next earnings date?
Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.10) earn...
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the following people: Mr. Mark J. Foley , CEO & Director (Age 57, Pay $1.4M) ( LinkedIn Profile )...
What is Mark Foley's approval rating as Revance Therapeutics' CEO?
7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com . Mark Foley has an approval rating of 82% among Revance Therapeutics'...
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Ultragenyx Pharmaceutical (RARE) , Blueprint Medicines (BPMC) , Arrowhead Pharma...
What other stocks do shareholders of Revance Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS) ,...
What is Revance Therapeutics?
What is the ticker symbol for Revance Therapeutics?
is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
What is marketbeat ratings?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How much does Revance Therapeutics make?
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote “Outperform” if you believe RVNC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Does Revance Therapeutics pay dividends?
How much money does Revance Therapeutics make? Revance Therapeutics has a market capitalization of $2.21 billion and generates $15.32 million in revenue each year . The biopharmaceutical company earns $-282,090,000.00 in net income (profit) each year or ($4.86) on an earnings per share basis.
What is Revance Therapeutics?
Revance Therapeutics does not currently pay a dividend.
Where is Revance Therapeutics located?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.